Recent strategies in the development of new human cytomegalovirus inhibitors

Medicinal Research Reviews

Volumn 21, Issue 3, 2001, Pages 227-244

  Martinez, Ana ^a   Castro, Ana ^a   Gil, Carmen ^a   Perez, Concepcion ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

HCMV inhibitors; HCMV protease; Immunocompromised patients; Opportunistic infection

Indexed keywords

ANTIRETROVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ATHEROSCLEROSIS; CYTOMEGALIC INCLUSION BODY DISEASE; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE DEFICIENCY; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; REVIEW; TREATMENT PLANNING;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG DESIGN; HUMANS; IMMUNOCOMPROMISED HOST; PROTEASE INHIBITORS; VIRAL VACCINES;

EID: 0035045772     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.1008     Document Type: Review

References (127)

1. Summary of the II International Symposium on Cytomegalovirus
2. Growth of human cytomegalovirus in primary macrophages
3. The dynamics of human cytomegalovirus replication in vivo
4. Coinfection of the immunocompromised but not the immunocompetent host by multiple human cytomegalovirus strains
5. Problems and progress in opportunistic infections
6. Active cytomegalovirus infection in human periodontitis
7. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation
8. Human cytomegalovirus strains associated with congenital and perinatal infections
9. Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after the treatment with highly active antiretroviral therapy
10. New strategies for the management of AIDS-related CMV retinitis in the era of potent antiretroviral therapy
11. Recent advances in the therapy and prevention of CMV infections
12. Resistance to antivirals in human cytomegalovirus: Mechanism and clinical significance
13. Resistance of human cytomegalovirus to antiviral drugs
14. Molecular analysis of the human cytomegalovirus strains isolated from infected infants
15. The possible role of human cytomegalovirus (HCMV) in the origin of atherosclerosis
16. Early atherosclerotic plaques in the aorta following cytomegalovirus infection of mice
17. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections
18. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis
19. Therapeutic potential of HPMPC as an antiviral drug
20. Fomivirsen: A phosphorothioate oligonucleotide for the treatment of CMV retinitis
21. Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovir
22. Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy
23. Ganciclovir resistance and UL97 gene mutations in cytomegalovirus blood isolates from patients with AIDS treated with ganciclovir
24. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922)
25. Gene therapy: Progress, new directions and issues
26. Regulation of transgene expression in genetic immunization
27. Human cytomegalovirus: Challenges opportunities and new drug development
28. Novel agents for the treatment of human cytomegalovirus infection
29. Pharmacokinetics, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: A phase I-II study
30. Application of the "Trimethyl Lock" to ganciclovir, a pro-drug with increased oral bioavailability
31. Design and synthesis of 6-fluoropurine acyclonucleosides: Potential prodrugs of acyclovir and ganciclovir
32. Synthesis and evaluation of 2-amino-9(1,3-dihydroxy-2-propoxymethyl)-6-fluoropurine mono- and diesters as potential prodrugs of ganciclovir
33. Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovir
34. Design of novel derivatives of phosphonoformate (foscarnet) as prodrugs and antiviral agents
35. Pronucleotides: Toward the in vivo delivery of antiviral and anticancer nucleotides
36. Synthesis, antiproliferative and antiviral activity of imidazo[4,5-d]isothiazole nucleosides as 5:5 fused analogs of nebularine and 6-methylpurine ribonucleoside
37. Synthesis and antiproliferative and antiviral activity of carbohydrate pyrrolo[2,3-c]pyridazin-7-one nucleosides
38. Synthesis and antiviral evaluation of certain novel pyrazinoic acid c-nucleosides
39. (R)-(-)- and (S)-(+)-Synadenol: Synthesis, absolute configuration, and enantioselectivity of antiviral effect
40. The cyclohexene ring system as a furanose mimic: Synthesis and antiviral activity of both enantiomers of cyclohexenylguanine
41. Spiropentane mimics of nucleosides: Analogues of 2′-deoxyadenosine and 2′-deoxyguanosine. Synthesis of all stereoisomers, isomeric assignment, and biological evaluation
42. Unusual single-stranded polyribonucleotides as potent anti-HIV agents
43. The role of hydrophobic versus hydrophilic base character in the anti-HIV activity of purine-containing polyribonucleotides
44. Antiviral oligo- and polyribonucleotides containing selected triazolo[2,3-a]purines
45. Novel pyrimidine and purine derivatives of L-ascorbic acid: Synthesis and biological evaluation
46. Synthesis and antiproliferative and antiviral activity of 2′-Deoxy-2′-fluoroarabinofuranosyl analogs of the nucleoside antibiotics toyocamycin and sangivamycin
47. Synthesis and evaluation of certain thiosangivamycin analogs as potential inhibitors of cell proliferation and human cytomegalovirus
48. Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and thiosangivamycin: Influence of various 7-substituents on antiviral activity
49. Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and thiosangivamycin: The effect of certain 4- and 4,6-Substituents on the antiviral activity of Pyrrolo[2,3-d]pyrimidines
50. Nonnucleoside pyrrolopyrimidines with a unique mechanism of action against human cytomegalovirus
51. Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(β-D-ribofuranosyl)benzimidazoles
52. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product
53. Comparison of benzimidazole nucleosides and ganciclovir on the in vivo proliferation and colony formation of human marrow progenitor cells
54. Synthesis and antiviral evaluation of certain 5′-modified analogs of 2,5,6-trichloro-1-(β-D-ribofuranosyl)benzimidazole
55. Synthesis and antiviral evaluation of halogenated -D- and L-erythrofuranosylbenzimidazoles
56. Structure-activity relationships among 2-substituted 5,6-dichloro-, 4,6- dichloro, and 4,5-dichloro-1-[(2-hydroxyethoxy)methyl]- and -1-[(1,3-dihydroxy-2-propoxy)methyl]benzimidazoles
57. Design, synthesis, and antiviral activity of α-nucleosides: D- and L-isomers of lyxofuranosyl- and (5-deoxyfuranosyl)benzimidazoles
58. Design, synthesis and antiviral activity of α-L-arabinofuranosyl derivatives of 2-substituted-5,6-dichlorobenzimidazoles
59. Design, synthesis, and antiviral evaluations of 1-(substitutedbenzyl)-2-substituted-5,6-dichlorobenzimidazoles as nonnucleoside analogues of 2,5,6-trichloro-1-(β-D-ribofuranosyl)benzimidazole
60. Design, synthesis and antiviral evaluation of 2-chloro-5,6-dihalo 1-β-D-ribofuranosylbenzimidazoles as potential agents for human cytomegalovirus infections
61. Studies designed to increase the stability and antiviral activity (HCMV) of the active benzimidazole nucleoside, TCRB
62. Synthesis of fluorosugar analogues of 2,5,6-trichloro-1-(β-D-ribofuranosyl)benzimidazole as antivirals with potentially increased glycosidic bond stability
63. Therapeutic nucleosides
64. Synthesis and antiviral evaluation of trisubstituted indole N-nucleosides as analogues of 2,5,6-trichloro-1-(β-D-ribofuranosyl)benzimidazole (TCRB)
65. Synthesis and antiviral evaluation of certain disubstituted benzimidazole ribonucleosides
66. Design, synthesis and antiviral evaluation of 2-substituted 4,5-dichloro- and 4,6-dichoro-1-β-D-ribofuranosylbenzimidazoles as potential agents for human cytomegalovirus infections
67. Benzimidazoles for the treatment of human cytomegalovirus
68. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: Novel antiviral mechanism of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
69. Synthesis and evaluation of a series of 2′-deoxy analogues of the antiviral agent 5,6-dichloro-2-isopropylamino-1-(β-L-ribofuranosyl)-1H-benzimidazole (1263W94)
70. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56
71. Design, synthesis, and biological evaluation of tricyclic nucleosides (dimensional probes) as analogues of certain antiviral polyhalogenated benzimidazole ribonucleosides
72. Structure-activity relationship of acyloxyamidine cytomegalovirus DNA polymerase inhibitors
73. Indolocarbazole: Potent, selective inhibitors of human cytomegalovirus replication
74. The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines
75. Discovery of 1,6-naphthyridines as a novel class of potent and selective human cytomegalovirus inhibitors
76. Isoquinoline-6-carboxamides as potent and selective anti-human cytomegalovirus (HCMV) inhibitors
77. Design and evaluation of dihydroisoquinolines as potent and orally bioavailable human cytomegalovirus inhibitors
78. Antiviral properties of a series of 1,6-naphthyridine and 7,8-dihydroisoquinoline derivatives exhibiting potent activity against human cytomegalovirus
79. Synthesis of C-acyclo-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents
80. Synthesis of imidazo[1,2-a]pyridines as antiviral agents
81. Benzothiadiazine dioxide acyclonucleosides as lead compounds for the development of new agents against human cytomegalovirus and varicella-zoster virus infections
82. Novel potential agents for human cytomegalovirus infection: Synthesis and antiviral activity evaluation of benzothiadiazine acyclonucleosides
83. Benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]thiadiazine 2,2-dioxides: First phosphodiesterase 7 inhibitors
84. Chlorophenylmethyl benzothiadiazine dioxides derivatives: Potent human cytomegalovirus inhibitors
85. Benzothiadiazine dioxides (BTD) dibenzyl derivatives as potent human cytomegalovirus inhibitors. Synthesis and comparative molecular field analysis
86. Nonnucleoside human cytomegalovirus inhibitors. Synthesis and antiviral evaluation of chlorophenylmethyl benzothiadiazine dioxides (BTD) derivatives
87. Assemblin, an essential herpesvirus proteinase
88. Herpesvirus proteases: Targets for novel antiviral drugs
89. Recent advances in antiviral research: Identification of inhibitors of the herpesvirus proteases
90. Assembly of the herpes simplex virus capsid: Characterization of intermediates observed during cell-free capsid formation
91. Activity of two-chain recombinant human cytomegalovirus protease
92. The herpesvirus protease: Mechanistic studies and discovery of inhibitors of the human cytomegalovirus protease
93. Comparison of human cytomegalovirus (HCMV) protease sequences among laboratory strains and seven clinical isolates
94. A rational approach towards successful crystallization and crystal treatment of human cytomegalovirus protease and its inhibitor complex
95. Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad
96. Three dimensional structure of human cytomegalovirus protease
97. Unique fold and active site in cytomegalovirus protease
98. A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease
99. Conserved mode of peptidomimetic inhibition and substrate recognition of human cytomegalovirus protease
100. Characterization of human cytomegalovirus protease as an induced-fit serine protease and the implications to the design of mechanism-based inhibitors
101. Peptidomimetic inhibitors of the human cytomegalovirus protease
102. Evidence of a conformational change in the human cytomegalovirus protease upon binding of peptidyl-activated carbonyl inhibitors
103. Human cytomegalovirus protease complexes its substrate recognition sequences in an extended peptide conformation
104. Design and synthesis of monocyclic β-lactams as mechanism-based inhibitors of human cytomelagovirus protease
105. Inhibition of human cytomegalovirus protease No with monocyclic β-lactams
106. Inhibition of human cytomegalovirus protease by monocyclic β-lactam derivatives: Kinetic characterization using fluorescent probe
107. β-Lactam derivatives as inhibitors of human cytomegalovirus protease
108. Synthesis and antiviral activity of monolactams inhibiting the human cytomegalovirus protease
109. Novel, selective mechanism-based inhibitors of herpes protease
110. Inhibition of human cytomegalovirus protease by benzoxazinones and evidence of antiviral activity in cell culture
111. Inhibition of HSV-1 protease by benzoxazinones
112. Potent selective thienoxazinone inhibitors of herpes proteases
113. Inhibition of herpes proteases and antiviral activity of 2-substituted thieno[2,3-d]oxazinones
114. Inhibition of human cytomegalovirus protease by enedione derivatives of thieno[2,3-d]oxazinones through a novel dual acylation/alkylation mechanism
115. The inhibition of human cytomegalovirus (hCMV) protease by hydroxylamine derivatives
116. A high throughput colorimetric cell proliferation assay for the identification of human cytomegalovirus inhibitors
117. Design of fluorogenic peptide substrates for human cytomegalovirus protease based on structure-activity relationship studies
118. Cytonic acids A and B: Novel tripepside inhibitors of hCMV protease from the endophytic fungus Cytonaema Species
119. Quanolirones I and II, two new human cytomegalovirus protease inhibitors produced by Streptomyces sp. WC76535
120. Benzothiopyran-4-one based reversible inhibitors of the human cytomegalovirus (HCMV) protease
121. 2-chloro-3-substituted-1,4-Naphthoquinone inactivators of human cytomegalovirus protease
122. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients
123. Little role of anti-gB antibodies in neutralizing activity of patient's sera with human cytomegalovirus infection
124. Development of biopharmaceuticals in plant expression systems: Cloning, expression and immunological reactivity of human cytomegalovirus glycoprotein B (UL55) in seeds of transgenic tobacoo
125. Induction of neutralizing antibody against human cytomegalovirus (HCMV) with DNA-mediated immunization of HCMV glycoprotein B in mice
126. DNA immunization confers protection against murine cytomegalovirus infection
127. Suppresion of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65)